Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis.
Proteomedix has raised $3.2M in total funding. The most recent round was Debt Financing. The last funding was announced in September 2021.
Proteomedix's investors include Altos Ventures, Zürcher Kantonal Bank, Venture Kick, New Horizon Health, Altos Venture.
Proteomedix is headquartered in Schlieren, Switzerland.
Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis.
Proteomedix is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Proteomedix — Funding & Investors." VCBacked, September 21, 2021, https://www.vcbacked.co/company/proteomedix. Accessed September 29, 2026.
VCBacked. (2021). Proteomedix — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/proteomedix
{{cite web |title=Proteomedix — Funding & Investors |url=https://www.vcbacked.co/company/proteomedix |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated